LILLE, France, February 20, 2019 / —AlzProtect, a biopharmaceutical company engaged in the development of drugs for the treatment of Alzheimer’s disease and Progressive Supranuclear Palsy (PSP), announced today the successful completion of the latest phase 1 study regarding the effect of food intake for its drug candidate AZP2006.

The phase 1 study was performed by analyzing the effect of food intake on the pharmacokinetic parameters following a single oral administration of AZP2006 to 14 healthy volunteers. The compound was well tolerated by all volunteers and its pharmacokinetics was moderately impacted following the absorption of a rich diet.The first phase 1 clinical studies done with 88 subjects had shown that after oral administration, AZP2006 was well absorbed by the intestine and well tolerated by healthy volunteers.

“AlzProtect, with this new success, has now all the elements necessary to apply for our next phase 2a study with PSP patients. The first patient recruitments will occur in 2019 ” said Philippe Verwaerde, president and scientific director of AlzProtect.